Solid preparation of cariprazine for oral administration

A technology of cariprazine and modified-release cariprazine, which is applied in the direction of non-active ingredient medical preparations, medical preparations containing active ingredients, pill delivery, etc., and can solve the problem of drug insolubility in neutral or alkaline environments And other issues
CN110769815AInactive Publication Date: 2020-02-07RICHTER GEDEON NYRT
9 Cites 5 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
RICHTER GEDEON NYRT
Publication Date
2020-02-07
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates oral phamiaceuticai compositions for the modified release delivery of cariprazine (trans-N-{4-[2-[4-(2,3-dichlorophenyl)-piperazin-l-yl]-ethyl]-cyclohexyl}-N',N'- dimethylurea) or pharmaceutically acceptable salts thereof for less than daily dosing. The invention also relates to the use of said compositions in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors. The invention also relates to the process for the preparation of said modified release pharmaceutical compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] field of invention

[0002] The present invention provides modified release delivery of cariprazine (trans-N-{4-[2-[4-(2,3-dichlorophenyl)- Oral pharmaceutical composition and method of piperazin-1-yl]-ethyl]-cyclohexyl}-N',N'-dimethylurea) or a pharmaceutically acceptable salt thereof.

[0003] Background of the invention

[0004] Cariprazine is a partial dopamine D3-preferential D3 / D2 receptor agonist. WO 2005 / 012266 A1 discloses cariprazine and pharmaceutically acceptable salts thereof. This document also discloses pharmaceutical compositions comprising cariprazine hydrochloride or other pharmaceutically acceptable salts, and their use in the treatment and / or prevention of pathological conditions requiring modulation of dopamine receptors, said pathological conditions Examples include psychosis (such as schizophrenia, schizoaffective disorder, etc.), substance abuse (such as alcohol, cocaine, nicotine, opioids, etc.), schizophrenia with cognitive impairment (includi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More